β遮断薬市場：タイプ、用途、流通チャネル別-2025-2030年の世界予測

β遮断薬市場は、2023年に105億4,000万米ドルと評価され、2024年には110億6,000万米ドルに達すると予測され、CAGR 5.23％で成長し、2030年には150億8,000万米ドルに達すると予測されています。

β遮断薬、すなわちβアドレナリン遮断薬は、主に高血圧、不整脈、心不全を含む様々な心血管疾患の管理に使用される医薬品です。その範囲は不安、片頭痛、ある種の緑内障の治療にも及び、その必要性と多様性を強調しています。これらの薬は、アドレナリンの作用を抑制することによって機能し、心拍数と血圧を低下させる。β遮断薬の世界市場は、心血管疾患有病率の上昇、人口の高齢化、治療オプションに対する意識の高まりによって牽引されています。β遮断薬の用途は病院、診療所、小売薬局に及び、最終用途の広さを示しています。業界の成長は、製剤技術の進歩、ヘルスケア支出の増加、公衆衛生インフラ強化の取り組みに大きく影響されています。ジェネリック医薬品の増加は、新興市場における潜在的なビジネスチャンスをもたらし、競争力のある価格設定とアクセスの拡大を促します。企業は、革新的なドラッグデリバリーシステムに投資したり、未開拓の地方市場を開拓したりすることで、こうした力学を活用することができます。しかし、規制上のハードル、厳格な医薬品承認、長期使用に伴う副作用などの課題に直面し、市場の成長が阻害される可能性があります。さらに、地域によっては経済が不安定になり、ヘルスケア予算、ひいては医薬品購入に影響を及ぼす可能性もあります。技術革新と研究の面では、より副作用の少ない、あるいは標的を絞ったデリバリー・システムの開発が競争優位性をもたらす可能性があります。さらに、より効果的な治療のために遺伝的要因や生活習慣に着目した個別化医療のアプローチは、研究にとって機が熟している分野です。同市場は競合が多いのが特徴で、主要企業は市場シェアを維持・拡大するために絶えず研究開発に投資しています。このため、β遮断薬市場の成長を目指す企業は、イノベーション、戦略的パートナーシップ、未開拓市場でのプレゼンス拡大に注力し、新たなチャンスを生かす必要があります。

市場力学：急速に進化するβ遮断薬市場の主要市場インサイトを公開

β遮断薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 心臓関連の疾患にかかりやすくなる高齢化人口の増加
  • うっ血性心不全、不整脈、甲状腺機能亢進症の管理におけるβ遮断薬の役割の増大
  • 政府やヘルスケア組織による公衆衛生への取り組みと意識向上プログラム
• 市場抑制要因
  • 製品回収の発生
• 市場機会
  • 高血圧の個別化β遮断薬開発のための研究開発活動の活発化
  • β遮断薬に関する新しい分析法の動向
• 市場の課題
  • β遮断薬の摂取に伴う副作用

ポーターのファイブフォース：β遮断薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、β遮断薬市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：β遮断薬市場における外部からの影響の把握

外部マクロ環境要因は、β遮断薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析β遮断薬市場における競合情勢の把握

β遮断薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスβ遮断薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、β遮断薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨β遮断薬市場における成功への道筋を描く

β遮断薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 高齢化が進むと心臓関連疾患にかかりやすくなる
    • うっ血性心不全、不整脈、甲状腺機能亢進症の管理におけるβ遮断薬の役割の増大
    • 政府やヘルスケア機関による公衆衛生の取り組みと啓発プログラム
  • 抑制要因
    • 製品リコールの発生率
  • 機会
    • 高血圧に対する個別化β遮断薬治療の開発に向けた研究開発（R&D）活動の拡大
    • β遮断薬の分析手法における新たな動向
  • 課題
    • β遮断薬の摂取に伴う副作用
• 市場セグメンテーション分析
  • タイプ：呼吸器疾患の懸念に対処するためのβ1選択的遮断薬の消費量の増加
  • 応用：さまざまな心血管疾患の管理におけるアドレナリンとしてのβ遮断薬の使用増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 β遮断薬市場：タイプ別

• ベータ非選択的遮断薬
  • ラベタロール
  • ペンブトロール硫酸塩
  • ピンドロール
  • ソタロール塩酸塩
• ベータ1選択的遮断薬
  • アセブトロール
  • アテノロール
  • ビソプロロール
  • メトプロロール

第7章 β遮断薬市場：用途別

• 心臓疾患
  • 狭心症
  • 心房細動
  • 心不全
• 緑内障
• 高血圧

第8章 β遮断薬市場：流通チャネル別

• 病院薬局
• 小売薬局

第9章 南北アメリカのβ遮断薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のβ遮断薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのβ遮断薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • FDAが活動性潰瘍性大腸炎の治療薬としてVELSIPITYを承認
  • 「新しい超短時間作用型ベータ遮断薬ランジオロールが、カナダで重篤な心臓疾患の治療薬として承認されました」
  • アジャンタファーマ、高血圧症をシンプルかつ効果的に管理できる新しい二重作用タブレット「Met-XL AMT」を発売
• 戦略分析と提言

企業一覧

• AdvaCare Pharma
• Amneal Pharmaceuticals LLC
• ANI Pharmaceuticals, Inc.
• AstraZeneca PLC
• Baxter International Inc.
• Bayer AG
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Cipla Limited
• DAIICHI SANKYO COMPANY, LIMITED
• Dr. Reddy's Laboratories Ltd.
• Eagle Pharmaceuticals, Inc.
• GlaxoSmithKline PLC
• Lupin Limited
• Merck & Co., Inc.
• Neuracle Lifesciences Private Limited
• Novartis AG
• Pfizer Inc.
• Recordati Industria Chimica e Farmaceutica S.p.A.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• The Menarini Group
• Viatris Inc.

LIST OF FIGURES

• FIGURE 1. BETA BLOCKERS MARKET RESEARCH PROCESS
• FIGURE 2. BETA BLOCKERS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BETA BLOCKERS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BETA BLOCKERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL BETA BLOCKERS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL BETA BLOCKERS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES BETA BLOCKERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES BETA BLOCKERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. BETA BLOCKERS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. BETA BLOCKERS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BETA BLOCKERS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BETA BLOCKERS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BETA BLOCKERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BETA BLOCKERS MARKET DYNAMICS
• TABLE 7. GLOBAL BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BETA BLOCKERS MARKET SIZE, BY LABETALOL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BETA BLOCKERS MARKET SIZE, BY PENBUTOLOL SULFATE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BETA BLOCKERS MARKET SIZE, BY PINDOLOL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BETA BLOCKERS MARKET SIZE, BY SOTALOL HYDROCHLORIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL BETA BLOCKERS MARKET SIZE, BY ACEBUTOLOL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL BETA BLOCKERS MARKET SIZE, BY ATENOLOL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL BETA BLOCKERS MARKET SIZE, BY BISOPROLOL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL BETA BLOCKERS MARKET SIZE, BY METOPROLOL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL BETA BLOCKERS MARKET SIZE, BY ANGINA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL BETA BLOCKERS MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL BETA BLOCKERS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL BETA BLOCKERS MARKET SIZE, BY GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL BETA BLOCKERS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL BETA BLOCKERS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL BETA BLOCKERS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 50. CANADA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. CANADA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 52. CANADA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 53. CANADA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 54. CANADA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 55. CANADA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. MEXICO BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 58. MEXICO BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 59. MEXICO BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. MEXICO BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 61. MEXICO BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 63. UNITED STATES BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 64. UNITED STATES BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 65. UNITED STATES BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. UNITED STATES BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 67. UNITED STATES BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 68. UNITED STATES BETA BLOCKERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 69. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 71. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 72. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 74. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 76. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 78. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 79. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 81. AUSTRALIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 82. CHINA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. CHINA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 84. CHINA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 85. CHINA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. CHINA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 87. CHINA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. INDIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. INDIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 90. INDIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 91. INDIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. INDIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 93. INDIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 94. INDONESIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. INDONESIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 96. INDONESIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 97. INDONESIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. INDONESIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 99. INDONESIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 100. JAPAN BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. JAPAN BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 102. JAPAN BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 103. JAPAN BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. JAPAN BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 105. JAPAN BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 106. MALAYSIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. MALAYSIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 108. MALAYSIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 109. MALAYSIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 110. MALAYSIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 111. MALAYSIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 112. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 114. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 115. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 116. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 117. PHILIPPINES BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 118. SINGAPORE BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. SINGAPORE BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 120. SINGAPORE BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 121. SINGAPORE BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. SINGAPORE BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 123. SINGAPORE BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 130. TAIWAN BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. TAIWAN BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 132. TAIWAN BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 133. TAIWAN BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 134. TAIWAN BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 135. TAIWAN BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 136. THAILAND BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. THAILAND BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 138. THAILAND BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 139. THAILAND BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. THAILAND BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 141. THAILAND BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 142. VIETNAM BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. VIETNAM BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 144. VIETNAM BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 145. VIETNAM BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 146. VIETNAM BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 147. VIETNAM BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 148. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 149. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 150. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 155. DENMARK BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 156. DENMARK BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 157. DENMARK BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 158. DENMARK BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 159. DENMARK BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 160. DENMARK BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 161. EGYPT BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 162. EGYPT BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 163. EGYPT BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 164. EGYPT BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 165. EGYPT BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 166. EGYPT BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 167. FINLAND BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 168. FINLAND BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 169. FINLAND BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 170. FINLAND BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 171. FINLAND BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 172. FINLAND BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 173. FRANCE BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 174. FRANCE BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 175. FRANCE BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 176. FRANCE BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 177. FRANCE BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 178. FRANCE BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 179. GERMANY BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 180. GERMANY BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 181. GERMANY BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 182. GERMANY BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 183. GERMANY BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 184. GERMANY BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 185. ISRAEL BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 186. ISRAEL BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 187. ISRAEL BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 188. ISRAEL BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 189. ISRAEL BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 190. ISRAEL BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 191. ITALY BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 192. ITALY BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 193. ITALY BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 194. ITALY BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 195. ITALY BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 196. ITALY BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 197. NETHERLANDS BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 198. NETHERLANDS BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 199. NETHERLANDS BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 200. NETHERLANDS BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 201. NETHERLANDS BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 202. NETHERLANDS BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 203. NIGERIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 204. NIGERIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 205. NIGERIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 206. NIGERIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 207. NIGERIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 208. NIGERIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 209. NORWAY BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 210. NORWAY BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 211. NORWAY BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 212. NORWAY BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 213. NORWAY BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 214. NORWAY BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 215. POLAND BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 216. POLAND BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 217. POLAND BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 218. POLAND BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 219. POLAND BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 220. POLAND BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 221. QATAR BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 222. QATAR BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 223. QATAR BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 224. QATAR BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 225. QATAR BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 226. QATAR BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 227. RUSSIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 228. RUSSIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 229. RUSSIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 230. RUSSIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 231. RUSSIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 232. RUSSIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 233. SAUDI ARABIA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 234. SAUDI ARABIA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 235. SAUDI ARABIA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 236. SAUDI ARABIA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 237. SAUDI ARABIA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 238. SAUDI ARABIA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 239. SOUTH AFRICA BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 240. SOUTH AFRICA BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 241. SOUTH AFRICA BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 242. SOUTH AFRICA BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 243. SOUTH AFRICA BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 244. SOUTH AFRICA BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 245. SPAIN BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 246. SPAIN BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 247. SPAIN BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 248. SPAIN BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 249. SPAIN BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 250. SPAIN BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 251. SWEDEN BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 252. SWEDEN BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 253. SWEDEN BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 254. SWEDEN BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 255. SWEDEN BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 256. SWEDEN BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 257. SWITZERLAND BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 258. SWITZERLAND BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 259. SWITZERLAND BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 260. SWITZERLAND BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 261. SWITZERLAND BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 262. SWITZERLAND BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 263. TURKEY BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 264. TURKEY BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 265. TURKEY BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 266. TURKEY BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 267. TURKEY BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 268. TURKEY BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 269. UNITED ARAB EMIRATES BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 270. UNITED ARAB EMIRATES BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 271. UNITED ARAB EMIRATES BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 272. UNITED ARAB EMIRATES BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 273. UNITED ARAB EMIRATES BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 275. UNITED KINGDOM BETA BLOCKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 276. UNITED KINGDOM BETA BLOCKERS MARKET SIZE, BY BETA NON-SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 277. UNITED KINGDOM BETA BLOCKERS MARKET SIZE, BY BETA-1 SELECTIVE BLOCKER, 2018-2030 (USD MILLION)
• TABLE 278. UNITED KINGDOM BETA BLOCKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 279. UNITED KINGDOM BETA BLOCKERS MARKET SIZE, BY CARDIAC DISEASES, 2018-2030 (USD MILLION)
• TABLE 280. UNITED KINGDOM BETA BLOCKERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 281. BETA BLOCKERS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 282. BETA BLOCKERS MARKET, FPNV POSITIONING MATRIX, 2023

The Beta Blockers Market was valued at USD 10.54 billion in 2023, expected to reach USD 11.06 billion in 2024, and is projected to grow at a CAGR of 5.23%, to USD 15.08 billion by 2030.

Beta blockers, or beta-adrenergic blocking agents, are pharmaceuticals primarily used to manage various cardiovascular conditions, including hypertension, arrhythmias, and heart failure. Their scope extends into treating anxiety, migraines, and certain types of glaucoma, highlighting their necessity and versatility. These medications function by inhibiting the effects of adrenaline, resulting in lowered heart rates and blood pressure. The global market for beta blockers is driven by rising cardiovascular disease prevalence, aging populations, and increasing awareness of treatment options. The application of beta blockers spans hospitals, clinics, and retail pharmacies, demonstrating their extensive end-use scope. Industry growth is significantly influenced by technological advancements in drug formulations, increasing healthcare spending, and initiatives to enhance public health infrastructure. The rise in generic drug formulations presents potential opportunities in emerging markets, encouraging competitive pricing and widening access. Companies can leverage these dynamics by investing in innovative drug delivery systems or exploring untapped rural markets. However, the market faces challenges, such as regulatory hurdles, strict drug approvals, and side effects associated with long-term use, which could inhibit growth. Additionally, economic instability in certain regions can impact healthcare budgets and, consequently, pharmaceutical purchases. In terms of innovation and research, developing beta blockers with fewer side effects or targeted delivery systems could offer a competitive edge. Furthermore, personalized medicine approaches, focusing on genetic and lifestyle factors for more effective treatment, present an area ripe for research. The market is characterized by high competition, with key players constantly investing in R&D to maintain or increase market share. Thus, businesses aiming for growth in the beta blockers market should focus on innovation, strategic partnerships, and expanding their presence in underserved markets to capitalize on unfolding opportunities.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Beta Blockers Market

The Beta Blockers Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising aging population more susceptible to heart-related conditions
  • Increasing role of beta blockers in managing congestive heart failure, cardiac arrhythmias, and hyperthyroidism
  • Public health initiatives and awareness programs by governments and healthcare organizations
• Market Restraints
  • Incidence of product recall
• Market Opportunities
  • Growing research and development (R&D) activities for the development of individualized beta-blocker treatment for high blood pressure
  • Novel trends in analytical methods for beta blockers
• Market Challenges
  • Side effects associated with the consumption of beta blockers

Porter's Five Forces: A Strategic Tool for Navigating the Beta Blockers Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Beta Blockers Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Beta Blockers Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Beta Blockers Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Beta Blockers Market

A detailed market share analysis in the Beta Blockers Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Beta Blockers Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Beta Blockers Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Beta Blockers Market

A strategic analysis of the Beta Blockers Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Beta Blockers Market, highlighting leading vendors and their innovative profiles. These include AdvaCare Pharma, Amneal Pharmaceuticals LLC, ANI Pharmaceuticals, Inc., AstraZeneca PLC, Baxter International Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla Limited, DAIICHI SANKYO COMPANY, LIMITED, Dr. Reddy's Laboratories Ltd., Eagle Pharmaceuticals, Inc., GlaxoSmithKline PLC, Lupin Limited, Merck & Co., Inc., Neuracle Lifesciences Private Limited, Novartis AG, Pfizer Inc., Recordati Industria Chimica e Farmaceutica S.p.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., The Menarini Group, and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Beta Blockers Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Beta Non-selective Blocker and Beta-1 Selective Blocker. The Beta Non-selective Blocker is further studied across Labetalol, Penbutolol Sulfate, Pindolol, and Sotalol Hydrochloride. The Beta-1 Selective Blocker is further studied across Acebutolol, Atenolol, Bisoprolol, and Metoprolol.
• Based on Application, market is studied across Cardiac Diseases, Glaucoma, and Hypertension. The Cardiac Diseases is further studied across Angina, Atrial Fibrillation, and Heart Failure.
• Based on Distribution Channel, market is studied across Hospital Pharmacies and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising aging population more susceptible to heart-related conditions
    • 5.1.1.2. Increasing role of beta blockers in managing congestive heart failure, cardiac arrhythmias, and hyperthyroidism
    • 5.1.1.3. Public health initiatives and awareness programs by governments and healthcare organizations
  • 5.1.2. Restraints
    • 5.1.2.1. Incidence of product recall
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing research and development (R&D) activities for the development of individualized beta-blocker treatment for high blood pressure
    • 5.1.3.2. Novel trends in analytical methods for beta blockers
  • 5.1.4. Challenges
    • 5.1.4.1. Side effects associated with the consumption of beta blockers
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Rising consumption of beta-1 selective blockers to address respiratory concerns
  • 5.2.2. Application: Increasing usage of beta blockers as an adrenaline in managing various cardiovascular conditions
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Beta Blockers Market, by Type

• 6.1. Introduction
• 6.2. Beta Non-selective Blocker
  • 6.2.1. Labetalol
  • 6.2.2. Penbutolol Sulfate
  • 6.2.3. Pindolol
  • 6.2.4. Sotalol Hydrochloride
• 6.3. Beta-1 Selective Blocker
  • 6.3.1. Acebutolol
  • 6.3.2. Atenolol
  • 6.3.3. Bisoprolol
  • 6.3.4. Metoprolol

7. Beta Blockers Market, by Application

• 7.1. Introduction
• 7.2. Cardiac Diseases
  • 7.2.1. Angina
  • 7.2.2. Atrial Fibrillation
  • 7.2.3. Heart Failure
• 7.3. Glaucoma
• 7.4. Hypertension

8. Beta Blockers Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacies
• 8.3. Retail Pharmacies

9. Americas Beta Blockers Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Beta Blockers Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Beta Blockers Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. FDA Approved VELSIPITY, An Advancement To Treat Active Ulcerative Colitis
  • 12.3.2. "New Ultra-Short-Acting Beta Blocker, Landiolol, Received Canadian Approval For Critical Care Cardiac Conditions
  • 12.3.3. Ajanta Pharma Launched Met-XL AMT, A New Dual-Action Tablet for Simplified and Effective Hypertension Management
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AdvaCare Pharma
• 2. Amneal Pharmaceuticals LLC
• 3. ANI Pharmaceuticals, Inc.
• 4. AstraZeneca PLC
• 5. Baxter International Inc.
• 6. Bayer AG
• 7. Boehringer Ingelheim International GmbH
• 8. Bristol-Myers Squibb Company
• 9. Cipla Limited
• 10. DAIICHI SANKYO COMPANY, LIMITED
• 11. Dr. Reddy's Laboratories Ltd.
• 12. Eagle Pharmaceuticals, Inc.
• 13. GlaxoSmithKline PLC
• 14. Lupin Limited
• 15. Merck & Co., Inc.
• 16. Neuracle Lifesciences Private Limited
• 17. Novartis AG
• 18. Pfizer Inc.
• 19. Recordati Industria Chimica e Farmaceutica S.p.A.
• 20. Sun Pharmaceutical Industries Ltd.
• 21. Teva Pharmaceutical Industries Ltd.
• 22. The Menarini Group
• 23. Viatris Inc.